Figure 2: MYC activation combined with Vhl and Ink4a/Arf loss results in histopathological changes in the kidney resembling human clear cell renal carcinomas. | Nature Communications

Figure 2: MYC activation combined with Vhl and Ink4a/Arf loss results in histopathological changes in the kidney resembling human clear cell renal carcinomas.

From: MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma

Figure 2

(a) Kaplan-Meier survival curve comparing survival rates between V (n=8), VM (n=21) and VIM (n=12) mice. Log rank V versus VM P=0.007, V versus VIM P<0.0001, VM versus VIM P<0.001. (b) Representative gross and H&E images of kidney sections from V (33 weeks), VM (30 weeks) and VIM (19 weeks) mice at the indicated times post Dox treatment. (scale bars, 200 and 100 μm). (c) cBioPortal OncoPrint plot showing the distribution of MYC, VHL and CDKN2A copy number alterations in the TCGA KIRC data set. (d) Kaplan–Meier survival curve comparing human kidney renal clear cell carcinomas with V, VM and VIM alterations. Log rank V versus VIM P=5.08e-9, V versus VM P=0.005, VM versus VIM P=0.200. (e) Bar graph showing the correlation of V, VM and VIM tumours from the TCGA KIRC dataset with stage and (f) metastasis. (g) Bar graphs showing percentage of TCGA KIRC tumours with alterations in VHL, CDKN2A, and MYC by TNM Stage. (e–g) *P<0.05; **P<0.01, ***P<0.001. P values obtained from Chi-square test.

Back to article page